trim estim fx tax rate
street est high given recent management remark
ahead zoetiss earn report februari adjust model base
recent commentari manag regard certain non-cor factor
specif management indic fx could neg headwind
revenu previous model tax rate
line initi guidanc due discret item
like repeat well effect gilti global
intang low-tax incom tax regul also make minor tweak
core estim result model call revenu
adjust ep respect importantli
believ mani sell-sid model yet adjust expect consensu gradual
move come week lower estim multipl compress
peer group trim po base price-to-earnings line
prior two-year zoeti multipl previous
focu remain guid expect
believ focu zoeti remain guid expect
earn call februari expect organ growth guid rang
exclud contribut abaxi acquisit adj ep approxim
question outbreak african swine fever asf china
europ impact global trade state us cattl herd enter fifth
year expans potenti anoth blockbust product launch
companion anim therapeut also top mind acknowledg topic
must close monitor involv risk upsid downsid
believ overal ah anim health market condit remain favor see
anoth strong year perform addit tailwind abaxi
acquisit capit deploy link
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
zoeti global leader discoveri
develop manufactur
commerci anim health medicin
vaccin product companion
anim market well-diversifi portfolio
product line span eight core
speci five therapeut categori directli
market countri industri
believ zoeti benefit rise
demand companion product anim
health product particularli emerg market
new product product line extens
expand ancillari servic offer greater
oper work capit effici
opportunist invest acquisit and/or
partnership supplement growth
po base approxim ep estim back
dcf assum wacc termin growth rate in-lin
current multipl well averag multipl past two year
justifi given upsid new product launch increment capit deploy
margin expans opportun defens natur busi
downsid risk price object competit select market weaker demand
anim health product regulatori issu macroeconom condit currenc risk
headwind relat regul antibiot use anim feed addit
michael ryskin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
